Previous 10 | Next 10 |
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, Mar...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30...
Gainers: Okta ( OKTA ) +13% . Kezar Life Sciences ( KZR ) +7% . Esperion Therapeutics. ( ESPR ) +6% . Syros Pharmaceuticals ( SYRS ) +5% . ImmunityBio ( IBRX ) +5% . Losers: Funko ( FNKO ) -27% . ZimVie ( ZIMV ...
Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Autoimmune/Complemen...
Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at th...
Summary Following a shift in market sentiment, I've narrowed my rating for Kezar Life Sciences from buy to hold. The market has heavily discounted KZR's growth catalysts of clinical trial updates and regulatory tailwinds. Market data also suggest a lack of buying support with ...
Overall renal responses (ORR), measured as 50% or greater reduction in proteinuria from baseline, increased from 11 of 17 patients (64.7%) at end of treatment (Week 25) to 15 of 17 patients (88.2%) at end of study (Week 37). The median UPCR at end of study was 0.32. Reductio...
Kezar Life Sciences press release ( NASDAQ: KZR ): Q3 GAAP EPS of -$0.25. Cash, cash equivalents and marketable securities totaled $290.4 million as of September 30, 2022, compared to $208.4 million as of December 31, 2021. Total shares of common stock outstanding were...
Presented positive complete results from the MISSION Phase 2 trial evaluating zetomipzomib in patients with lupus nephritis at ASN’s Kidney Week 2022 Annual Meeting Received FDA clearance of IND for zetomipzomib for the treatment of autoimmune hepatitis Cash, ...
Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean reduction of background corticosteroid use. ORRs increased to 94.1% at Week 29...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...